LLY Stock: Should You Buy After A 20% Rise?
We believe there is minimal cause for concern with LLY stock, which makes it attractive but highly sensitive to adverse ...
BioPharma Dive15d
Lilly expands US manufacturing build-out with $50B target
The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...
Al Jazeera on MSN15d
Eli Lilly plans $27bn in new plants as Trump threatens pharma tariffs
Eli Lilly plans to spend at least $27bn to build four new manufacturing plants in the United States, the drugmaker has said ...
Eli Lilly comes for knockoff weight loss drugs in new ad campaign
Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, launched a new advertising campaign on Friday ...
Hosted on MSN21d
Eli Lilly wants to use its weight loss drug windfall to fight Alzheimer's and hearing loss
Medical bottles and syringe are seen with Eli Lilly and Company logo displayed on a screen in the background in this illustration photo taken in Krakow, Poland on November 10, 2022. The weight ...
Eli Lilly & Co. stock underperforms Friday when compared to competitors
Shares of Eli Lilly & Co. LLY slid 4.73% to $869.58 Friday, on what proved to be an all-around positive trading session for ...
USA Today15d
Eli Lilly will build 4 new manufacturing sites to increase domestic drug production
Eli Lilly and Co. Wednesday announced plans to build four pharmaceutical manufacturing sites in the United States, significantly boosting domestic medicine production and adding around 13,000 ...
Morgan Stanley sees ‘limited impact’ to Lilly shares from Novo CagriSema data
Morgan Stanley analyst Terence Flynn notes that Novo Nordisk (NVO) reported CagriSema Phase 3 data in type two diabetes demonstrating weight ...